A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.
Overview
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China is a phase 1/2 interventional study registered as NCT05009329 by Allist Pharmaceuticals, Inc., with 315 participants enrolled, started 2021-07-26 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-21822.
Similar pages
not linked directly; found by shared links- TrialA Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Shares Glecirasib, Shanghai Allist Pharmaceuticals and the tag pipeline.
- TrialTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TrialEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Shares Glecirasib, Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TreatmentSitneprotafib
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.